BIGT.L vs. XGES.L

Last updated Jun 5, 2026

BIGT.L (L&G Pharma Breakthrough UCITS ETF) and XGES.L (Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C) are both Health & Biotech Equities funds - BIGT.L tracks the NASDAQ Biotechnology TR USD while XGES.L tracks the MSCI World/Health Care NR USD. Both are passively managed. Over the past 3 years, BIGT.L returned 2.96%/yr vs 1.51%/yr for XGES.L. A 0.73 correlation means they provide meaningful diversification when combined. BIGT.L charges 0.49%/yr vs 0.35%/yr for XGES.L.

Performance

BIGT.L vs. XGES.L - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in L&G Pharma Breakthrough UCITS ETF (BIGT.L) and Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGES.L). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

BIGT.L is traded in GBp, while XGES.L is traded in GBP. To make them comparable, the XGES.L values have been converted to GBp using the latest available exchange rates.

Returns By Period

In the year-to-date period, BIGT.L achieves a -0.70% return, which is significantly higher than XGES.L's -0.81% return.

BIGT.L

• 1D: 2.65%
• 1M: -4.10%
• YTD: -0.70%
• 6M: -3.42%
• 1Y: 26.08%
• 3Y*: 2.96%
• 5Y*: 2.49%
• 10Y*: —

XGES.L

• 1D: 4.22%
• 1M: 5.53%
• YTD: -0.81%
• 6M: -4.20%
• 1Y: 26.55%
• 3Y*: 1.51%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BIGT.L vs. XGES.L - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
BIGT.L L&G Pharma Breakthrough UCITS ETF	-0.70%	27.03%	-3.16%	-14.88%	2.97%
XGES.L Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C	-0.81%	11.22%	-1.38%	-7.92%	-8.46%

Correlation

The correlation between BIGT.L and XGES.L is 0.79, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.79
Correlation (3Y) Calculated over the trailing 3-year period	0.73
Correlation (All Time) Calculated using the full available price history since Jul 21, 2022	0.73

The correlation between BIGT.L and XGES.L has been stable across timeframes, ranging from 0.73 to 0.79 - a consistent structural relationship.

Return for Risk

BIGT.L vs. XGES.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIGT.L

BIGT.L Risk / Return Rank: 43
BIGT.L Sharpe Ratio Rank: 40
BIGT.L Sortino Ratio Rank: 41
BIGT.L Omega Ratio Rank: 37
BIGT.L Calmar Ratio Rank: 53
BIGT.L Martin Ratio Rank: 45

XGES.L

XGES.L Risk / Return Rank: 37
XGES.L Sharpe Ratio Rank: 42
XGES.L Sortino Ratio Rank: 43
XGES.L Omega Ratio Rank: 38
XGES.L Calmar Ratio Rank: 35
XGES.L Martin Ratio Rank: 29

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIGT.L vs. XGES.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for L&G Pharma Breakthrough UCITS ETF (BIGT.L) and Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGES.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BIGT.L	XGES.L	Difference
Sharpe ratio: Return per unit of total volatility	1.39	1.45	-0.06
Sortino ratio: Return per unit of downside risk	2.04	2.15	-0.11
Omega ratio: Gain probability vs. loss probability	1.24	1.25	-0.01
Calmar ratio: Return relative to maximum drawdown	2.57	1.69	+0.88
Martin ratio: Return relative to average drawdown	7.42	4.09	+3.33
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BIGT.L vs. XGES.L - Sharpe Ratio Comparison

The current BIGT.L Sharpe Ratio is 1.39, which is comparable to the XGES.L Sharpe Ratio of 1.45. The chart below compares the historical Sharpe Ratios of BIGT.L and XGES.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BIGT.L	XGES.L	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.39	1.45	-0.06
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.15	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	-0.12	+0.34

Drawdowns

BIGT.L vs. XGES.L - Drawdown Comparison

The maximum BIGT.L drawdown since its inception was -30.23%, smaller than the maximum XGES.L drawdown of -35.79%. Use the drawdown chart below to compare losses from any high point for BIGT.L and XGES.L.

Drawdown Indicators

	BIGT.L	XGES.L	Difference
Max Drawdown Largest peak-to-trough decline	-30.23%	-35.79%	+5.56%
Max Drawdown (1Y) Largest decline over 1 year	-9.93%	-15.29%	+5.36%
Max Drawdown (3Y) Largest decline over 3 years	-23.09%	-25.52%	+2.43%
Max Drawdown (5Y) Largest decline over 5 years	-30.23%	—	—
Current Drawdown Current decline from peak	-5.41%	-12.59%	+7.18%
Average Drawdown Average peak-to-trough decline	-10.57%	-17.98%	+7.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.45%	6.34%	-2.89%

Volatility

BIGT.L vs. XGES.L - Volatility Comparison

L&G Pharma Breakthrough UCITS ETF (BIGT.L) and Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGES.L) have volatilities of 6.35% and 6.45%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BIGT.L	XGES.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.35%	6.45%	-0.10%
Volatility (6M) Calculated over the trailing 6-month period	14.10%	13.62%	+0.48%
Volatility (1Y) Calculated over the trailing 1-year period	18.38%	17.84%	+0.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.86%	18.27%	-1.41%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.38%	18.27%	+0.11%

BIGT.L vs. XGES.L - Expense Ratio Comparison

BIGT.L has a 0.49% expense ratio, which is higher than XGES.L's 0.35% expense ratio.

Dividends

BIGT.L vs. XGES.L - Dividend Comparison

Neither BIGT.L nor XGES.L has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both BIGT.L and XGES.L in my portfolio?

BIGT.L and XGES.L have a correlation of 0.79, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, BIGT.L or XGES.L?

On fees, XGES.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, BIGT.L or XGES.L?

XGES.L is cheaper with a 0.35% expense ratio, compared with 0.49% for BIGT.L.

What is the main difference between BIGT.L and XGES.L?

BIGT.L tracks NASDAQ Biotechnology TR USD, while XGES.L tracks MSCI World/Health Care NR USD. They also come from different issuers: Legal & General and DWS. Their fees differ too: 0.49% for BIGT.L and 0.35% for XGES.L.